{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "KRAS",
      "MEK",
      "RAF",
      "cancer",
      "targeted therapy resistance"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "35966590",
  "DateCompleted": {
    "Year": "2022",
    "Month": "08",
    "Day": "16"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "03",
    "Day": "08"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2022",
        "Month": "07",
        "Day": "18"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.7150/thno.71260"
    ],
    "Journal": {
      "ISSN": "1838-7640",
      "JournalIssue": {
        "Volume": "12",
        "Issue": "13",
        "PubDate": {
          "Year": "2022"
        }
      },
      "Title": "Theranostics",
      "ISOAbbreviation": "Theranostics"
    },
    "ArticleTitle": "Conquering oncogenic KRAS and its bypass mechanisms.",
    "Pagination": {
      "StartPage": "5691",
      "EndPage": "5709",
      "MedlinePgn": "5691-5709"
    },
    "Abstract": {
      "AbstractText": [
        "Aberrant activation of KRAS signaling is common in cancer, which has catalyzed heroic drug development efforts to target KRAS directly or its downstream signaling effectors. Recent works have yielded novel small molecule drugs with promising preclinical and clinical activities. Yet, no matter how a cancer is addicted to a specific target - cancer's genetic and biological plasticity fashions a variety of resistance mechanisms as a fait accompli, limiting clinical benefit of targeted interventions. Knowledge of these mechanisms may inform combination strategies to attack both oncogenic KRAS and subsequent bypass mechanisms."
      ],
      "CopyrightInformation": "\u00a9 The author(s)."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Center for Cell Signaling, Rutgers New Jersey Medical School, Newark, New Jersey 07103, USA."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of Microbiology, Biochemistry and Molecular Genetics, Rutgers New Jersey Medical School, Newark, New Jersey 07103, USA."
          },
          {
            "Identifier": [],
            "Affiliation": "Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA."
          },
          {
            "Identifier": [],
            "Affiliation": "Lead contact."
          }
        ],
        "LastName": "Hou",
        "ForeName": "Pingping",
        "Initials": "P"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA."
          }
        ],
        "LastName": "Wang",
        "ForeName": "Y Alan",
        "Initials": "YA"
      }
    ],
    "GrantList": [
      {
        "GrantID": "K22 CA251491",
        "Acronym": "CA",
        "Agency": "NCI NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R01 CA231349",
        "Acronym": "CA",
        "Agency": "NCI NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review",
      "Research Support, N.I.H., Extramural",
      "Research Support, U.S. Gov't, Non-P.H.S."
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Australia",
    "MedlineTA": "Theranostics",
    "NlmUniqueID": "101552395",
    "ISSNLinking": "1838-7640"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "KRAS protein, human"
    },
    {
      "RegistryNumber": "EC 3.6.5.2",
      "NameOfSubstance": "Proto-Oncogene Proteins p21(ras)"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "Carcinogenesis"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "drug therapy",
        "genetics"
      ],
      "DescriptorName": "Neoplasms"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Oncogenes"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "Proto-Oncogene Proteins p21(ras)"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Signal Transduction"
    }
  ],
  "CoiStatement": "Competing Interests: The authors have declared that no competing interest exists."
}